SGT 53

Drug Profile

SGT 53

Alternative Names: p53-gene-therapy-SynerGene; TfRscFv-Liposome-p53 Complex

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SynerGene Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference; P53 gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 13 Jun 2018 SynerGene Therapeutics plans a phase I trial for CNS Cancer (Recurrent, In children) in USA , (NCT03554707)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top